Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

MoonLake Immunotherapeutics (MLTX) Equity Average (2021 - 2026)

MoonLake Immunotherapeutics' Equity Average history spans 6 years, with the latest figure at $279.3 million for Q1 2026.

  • Quarterly Equity Average fell 35.01% to $279.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $279.3 million through Mar 2026, down 35.01% year-over-year, with the annual reading at $375.7 million for FY2025, 21.76% down from the prior year.
  • Equity Average came in at $279.3 million for Q1 2026, down from $296.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $541.2 million in Q2 2024 to a low of -$18.5 million in Q1 2022.
  • The 5-year median for Equity Average is $323.4 million (2025), against an average of $311.3 million.
  • The largest YoY upside for Equity Average was 11775.35% in 2022 against a maximum downside of 1236.66% in 2022.
  • MoonLake Immunotherapeutics' Equity Average stood at $75.7 million in 2022, then skyrocketed by 562.86% to $501.6 million in 2023, then dropped by 6.06% to $471.2 million in 2024, then plummeted by 37.03% to $296.7 million in 2025, then decreased by 5.88% to $279.3 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Equity Average are $279.3 million (Q1 2026), $296.7 million (Q4 2025), and $323.4 million (Q3 2025).